A Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and central nervous system activity of CY6463 when administered to participants with Alzheimer’s disease with vascular pathology
Chad Glasser
◽
Jennifer Chickering
◽
Phebe Wilson
◽
Emily Florine
◽
Chris Winrow
◽
...
2012 ◽
Vol 18
(9)
◽
pp. 1430-1437
◽
Petros Christopoulos
◽
Hartmut Bertz
◽
Gabriele Ihorst
◽
Reinhard Marks
◽
Ralph Wäsch
◽
...
1959 ◽
Vol 48
(2)
◽
pp. 122-126
◽
C.L. Mitchell
◽
H.H. Keasling
◽
E.G. Gross
1977 ◽
Vol 20
(3)
◽
pp. 379-386
◽
I. R. Ager
◽
D. R. Harrison
◽
P. D. Kennewell
◽
J. B. Taylor
1982 ◽
Vol 34
(4)
◽
pp. 870-902
1974 ◽
Vol 5
(36)
◽
pp. no-no
L. A. WALTER
◽
W. K. CHANG
◽
J. KENNEY
◽
I. DOUVAN
2002 ◽
Vol 9
(6)
◽
pp. 501-507
◽
M.H. Al-Yousuf
◽
B.H. Ali
◽
A.K. Bashir
◽
M.O.M. Tanira
◽
G. Blunden
2018 ◽
Vol 10
(4)
◽
pp. 339
Akash Ved
◽
Amresh Gupta
◽
Om Prakash
◽
AjayKumar Singh Rawat
Daniel R. Swale
◽
Aaron D. Gross
◽
Quentin R. R. Coquerel
◽
Jeffrey R. Bloomquist
1977 ◽
Vol 8
(39)
◽
pp. no-no
C. F. TURK
◽
J. KRAPCHO
◽
I. M. MICHEL
◽
I. WEINRYB
Close
Export Citation Format
Close
Share Document
Close